Section Arrow
TRDA.NASDAQ
- Entrada Therapeutics
Quotes are at least 15-min delayed:2025/11/19 03:46 EST
Pre Market
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 8.82
+0.35 (+4.13%)
Day High 
9.115 
Prev. Close
8.47 
1-M High
9.1499 
Volume 
351.07K 
Bid
--
Ask
--
Day Low
8.3 
Open
8.46 
1-M Low
5.81 
Market Cap 
323.72M 
Currency USD 
P/E 8.66 
%Yield -- 
10-SMA 7.64 
20-SMA 7.22 
50-SMA 6.3 
52-W High 21.79 
52-W Low 4.93 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.57/-4.57
Enterprise Value
375.36M
Balance Sheet
Book Value Per Share
8.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
210.78M
Operating Revenue Per Share
2.28
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CANFCan-Fite BioPharma Ltd0.3801+0.0181+5.00%-- 
Pre Market -- -- --
ASBPAspire Biopharma Holdings Inc.0.1057+0.0144+15.77%-- 
Pre Market -- -- --
OLMAOlema Pharmaceuticals20.14+11.62+136.38%-- 
Pre Market -- -- --
CMNDClearmind Medicine0.2164-0.0605-21.85%0.16PE
Pre Market -- -- --
APLTApplied Therapeutics0.2984+0.0142+5.00%-- 
Pre Market -- -- --
Quotes are at least 15-min delayed:2025/11/19 03:46 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.